← Back to all trials
Completed
NCT07723716
Evaluate the Efficacy and Safety of CTO0307 in Adults With Presbyopia
Conditions: Presbyopia
Sex: All
Ages: 40 Years – 65 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 167
Sponsor: Taejoon Pharmaceutical Co., Ltd.
Location: Kangbook Samsung Medical Center Seoul
Summary
This study was to compare the presbyopia correction effect between the treatment group and the control group, evaluated by the proportion of patients who achieved an improvement of 3 lines or more in mesopic binocular DCNVA at 3 hours post-dose after 4 weeks of administration of the investigational product.
Eligibility Criteria
Inclusion Criteria:
1. Men and women aged ≥40 years and \
Source: ClinicalTrials.gov (NCT07723716). StuddyBuddy aggregates publicly available trial information.
